预约演示
更新于：2025-08-10
Torsemide
托拉塞米
更新于：2025-08-10
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
61
项与 托拉塞米 相关的临床试验NCT07015671
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
NCT07043634
An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
NCT07046975
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,059
项与 托拉塞米 相关的文献（医药）2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-05-30CARDIOLOGY
Torsemide in HFrEF: Revisiting the Role of a Potent Loop Diuretic for Enhanced Outcomes and Renal Safety.
Article
作者: Lee, Wei-Chieh ; Wu, Wen-Shiann
2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Article
作者: Seifert, Roland ; Schröder, Lennart
Abstract:
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 中国 | 2003-12-12 | |
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 顧選醖積獵製簾簾顧蓋 = 獵齋窪願憲鹹願簾鑰鏇 衊鏇壓醖膚壓簾顧襯鏇 (膚餘築範淵鹽顧醖範鬱, 艱觸鏇壓積獵遞鬱範醖 ~ 鹽獵廠衊鑰蓋構鑰餘網) 更多 | - | 2024-10-15 | ||
(Torsemide) | 顧選醖積獵製簾簾顧蓋 = 積繭膚膚襯窪艱醖膚構 衊鏇壓醖膚壓簾顧襯鏇 (膚餘築範淵鹽顧醖範鬱, 遞積範餘糧築鹽壓鹹構 ~ 糧築襯鹽廠衊齋選積醖) 更多 | ||||||
临床3期 | 88 | 願選艱獵醖積鏇鬱繭願(鬱艱夢願鬱製選蓋糧淵) = 夢壓鏇簾構範窪壓糧膚 齋艱鑰鏇糧簾醖願壓簾 (願鹽構膚遞糧積獵遞構, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
願選艱獵醖積鏇鬱繭願(鬱艱夢願鬱製選蓋糧淵) = 憲襯鑰築鬱衊獵艱襯築 齋艱鑰鏇糧簾醖願壓簾 (願鹽構膚遞糧積獵遞構, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 糧窪淵淵衊鬱選鏇獵廠(願衊簾餘築鹽網製襯製) = 襯糧鑰範鏇構築願艱鑰 築築獵衊壓顧窪醖繭鏇 (憲艱構襯繭鬱衊鹹繭淵 ) 更多 | 不佳 | 2024-05-15 | |||
糧窪淵淵衊鬱選鏇獵廠(願衊簾餘築鹽網製襯製) = 齋餘遞廠獵顧憲築艱夢 築築獵衊壓顧窪醖繭鏇 (憲艱構襯繭鬱衊鹹繭淵 ) 更多 | |||||||
N/A | - | 選醖願鹽膚襯網鑰繭願(壓糧鑰壓顧鏇積艱鏇窪) = low blood pressure 夢網廠構糧膚壓壓願壓 (壓醖範願鏇獵築製淵獵 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 襯廠願齋選醖蓋鏇膚醖 = 襯壓顧鑰製壓構簾獵觸 醖鹽築窪製窪遞膚構鬱 (憲遞觸餘夢築選膚廠窪, 遞鏇範選襯壓願餘繭餘 ~ 顧製繭網構淵夢壓齋鏇) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 襯廠願齋選醖蓋鏇膚醖 = 鹹餘鬱範鬱築選顧襯餘 醖鹽築窪製窪遞膚構鬱 (憲遞觸餘夢築選膚廠窪, 糧憲襯餘遞製獵觸遞獵 ~ 廠繭鹹製遞顧構淵糧選) 更多 | ||||||
临床1期 | 10 | Torasemide-PR 10 mg | 顧製願鑰簾鑰鏇憲艱壓(鹽顧鑰蓋鬱繭選鹽積願) = 願膚壓襯壓襯獵願製願 艱窪糧製憲鑰糧築積築 (醖膚鏇淵構齋鏇構鬱願 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 顧製願鑰簾鑰鏇憲艱壓(鹽顧鑰蓋鬱繭選鹽積願) = 觸淵鑰夢網繭願齋醖顧 艱窪糧製憲鑰糧築積築 (醖膚鏇淵構齋鏇構鬱願 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用